Rainmed Medical Forges Strategic Alliances with Industry Leaders to Accelerate Vascular Interventional Robotics Ecosystem
Recently, Rainmed Medical has successively partnered with top-tier private equity investment platforms in ChinaPing An Capital, multinational tech giantsGE Healthcare China, A Leading Medical Device Service Platform in ChinaChina Resources Medical Devices, Leading Private Enterprise in Pharmaceutical DistributionJointown Medical Devices, A Leading Domestic Investment Management Institution for Cardiovascular HospitalsHanxi PutaiEstablish strategic partnerships with top-tier enterprises.
Through a series of strategic collaborations, Rainmed Medical has built a high-end “circle of partners” in the field of precision diagnosis and treatment.Jointly advance capital operations, technological innovation, marketing, and channel development to accelerate the construction of the vascular interventional surgical robot ecosystem and the implementation of strategic initiatives., to better empower clinicians and benefit patients with cardiovascular diseases both in China and abroad.
Strategic Cooperation Signing Ceremony Group Photo
Runmaide Medical is committed to becoming a leading company in vascular interventional surgical robotics, currently focusing on the design, research and development, and commercialization of coronary functional diagnosis and treatment products, having created a series of groundbreaking functional diagnostic and therapeutic solutions.
In Scientific Research and Academia, the Company has continuously advanced research collaborations with leading medical centers both domestically and internationally, and has published more than twenty landmark clinical research articles in top-tier journals;In terms of capital operations, the company efficiently completed two rounds of financing within one year, paving the way for a smooth entry into the capital markets;In Marketing, the company rapidly achieved the commercial implementation of precision diagnostic and therapeutic technologies, with its products adopted by nearly 1,000 hospitals, and has fully entered the strategic implementation phase for vascular interventional surgical robots;In production quality control, the company has continuously increased its investment in capacity expansion and equipment upgrades, establishing a production system and supply chain network that are industry-leading.
The remarkable achievements of Rainmed Medical, along with its ambitious vision to build a globally leading company in vascular interventional surgical robotics, have attracted significant attention from prominent industry investors, technology companies, logistics platforms, and hospital groups, fostering the establishment of close strategic partnerships.
Strategic Partner Companies
The company’s rapid growth has attracted widespread attention from investment institutions. Recently, Ping An Capital led the Series D financing round of Rainmed Medical with an investment of tens of millions of US dollars, followed by participation from well-known international asset management firms. Following this round of financing, the company’s valuation has increased significantly, and various initiatives are being accelerated. Ping An Capital expressed strong recognition of Rainmed Medical’s advanced product concepts, robust scientific research capabilities, strong management expertise, and efficient execution abilities.Expanded the scope of cooperation with Rainmed Medical and signed a strategic cooperation agreement to jointly promote the implementation of collaborations in technological innovation, capital operations, and ESG.。
Mr. Liu Dong, Chairman of Ping An Capital, praised the achievements currently attained by Rainmed Medical and expressed his anticipation for future collaboration. He stated, “As the core private equity platform of Ping An Group,”Ping An Capital has both the responsibility and the capability to accelerate Rainmed Medical’s improvement of its commercialization network and the clinical adoption of its products. In the future, Ping An Capital will continue to support Rainmed Medical in the ongoing R&D of revolutionary diagnostic and therapeutic products, and in implementing its strategy for vascular interventional surgical robots, thereby benefiting patients both in China and overseas..”
RainMed Medical has long adhered to independent research and development, striving to become a leading enterprise in vascular interventional surgical robotics. The platform-based capabilities of its vascular interventional surgical robot, along with the advanced concept of the unmanned operating room, have attracted the attention of numerous technology companies both domestically and internationally, many of which have proposed establishing strategic partnerships with RainMed Medical.
As a global leader in the manufacturing of interventional imaging equipment, GE Healthcare China adheres to its mission of “driving innovation by clinical needs” and strives continuously to provide comprehensive disease management solutions for physicians and patients. The strategic partnership between GE Healthcare China and Rainmed Medical,Guided by clinical needs, we will establish innovative diagnostic and therapeutic models for coronary artery disease, explore refined catheterization laboratory management strategies, and organically integrate imaging-based and physiology-based diagnostics to achieve more precise coronary interventions., to better serve interventional cardiologists and patients with cardiovascular diseases.
Rainmed Medical’s series of digital functional diagnostic modules boast globally leading advantages, including safety, precision, efficiency, convenience, and pioneering innovation, spearheading the transformation and advancement of coronary artery disease detection. Industry sales giants and platform companies are actively seeking next-generation revolutionary technologies and have proactively proposed in-depth collaborations with Rainmed Medical to comprehensively facilitate the clinical adoption of these new technologies.
Chen Wei, a senior executive of China Resources Pharmaceutical Commercial Group, explicitly stated that China Resources places significant emphasis on medical devices, with cardiovascular and cerebrovascular devices being a key strategic focus. The collaboration with Rainmed Medical will introduce globally leading diagnostic and therapeutic products to the platform.Following the signing of a strategic cooperation agreement, Rainmed Medical and China Resources Medical Devices will deepen their exchanges, continuously launch new products, achieve more comprehensive product coverage, and maintain strong competitiveness in the market.
Amid the pandemic, Rainmed Medical achieved counter-trend growth, driving rapid expansion of its domestic sales revenue, with its caFFR product leading the market for Chinese-made FFR products. Jointown Pharmaceutical Group Co., Ltd., a leader among China’s private pharmaceutical distribution enterprises, has established the largest professional pharmaceutical supply chain service platform in the country.
Jointown Medical Devices, a subsidiary of Jointown Pharmaceutical Group, is committed to building China’s most professional medical device platform service provider. Vice Chairman Fu Xiong highly praised Rainmed’s courage in facing challenges head-on and its robust capabilities in achieving overtaking on the bend. He stated: “Our collaboration with Rainmed Medical has been reassuring and reliable. We hope that both parties will promptly establish a direct communication channel, ensure seamless business integration, leverage our respective resource advantages, continuously innovate, and unlock deeper value to build China’s most professional supply chain for cardiovascular medical devices.”
In addition to medical distribution and platform companies such as China Resources Medical Devices and Jointown Medical Devices, cardiovascular hospitals in China also place great emphasis on the application of precise assessment for cardiovascular diseases and are actively seeking leading automated technologies for precise diagnosis and treatment. As the first company to gain market access in both China and the European Union, Rainmed’s clinical and research value has been consistently affirmed by experts and scholars both domestically and internationally.
Hanxi Putai, a leading domestic investment and management institution for cardiovascular hospitals, is committed to building a high-quality medical service platform for cardiovascular health. Its collaboration with Rainmed Medical will significantly enhance Hanxi Putai’s comprehensive competitiveness.Hao Jiansheng, Chairman of Hanxi Putai, expressed high expectations for this collaboration. He hopes that both parties will comprehensively cooperate in areas such as clinical research and health management to build a robust medical service system.
RainMed Medical Interventional Surgical Robot
As the company’s overall strength grows,Rainmed Medical has gradually established close partnerships with leading enterprises in the fields of healthcare investment, medical technology, medical device distribution, and specialized hospitals.. In the future, leveraging the high-end “circle of friends” in precision diagnosis and treatment formed by strategic partners such as Ping An Capital, GE Healthcare China, and China Resources Medical Devices, Rainmed Medical’s strategy for vascular interventional surgical robots will be comprehensively accelerated in capital operations, pipeline R&D, marketing, and other areas.
In the future, Rainmed Medical will continue to uphold independent innovation and dedicated R&D, actively leverage its industry-leading role as a domestic high-tech medical device company, promote corporate spirit, and continuously develop groundbreaking advanced vascular diagnosis and treatment products such as vascular interventional surgical robots. By facilitating the clinical application of cutting-edge diagnostic and therapeutic technologies and building a high-quality healthcare ecosystem, Rainmed Medical is committed to making its utmost contribution to accelerating the realization of the strategic goals of Healthy China.